Biomerica reported a 27% narrower Q4 net loss of $1.1 million, with net sales increasing 17% to $0.875 million. Fiscal 2026 net loss decreased 24% to $3.8 million, while net sales declined to $4.50 million. The company had $1.3 million in cash and cash equivalents as of May 31, 2026, and completed a private placement of 1.39 million shares of common stock in August 2026.

Biomerica

Biomerica Narrows Q4 Loss, Revenue Up 17% Y/Y; Stock Down

Biomerica reported FY GAAP EPS of -$1.30 and revenue of $4.5M, a 15.1% Y/Y decline. The company had approximately $1.3M in cash and cash equivalents as of May 31, 2026, compared to $2.4M as of May 31, 2025.

Biomerica Reports Q4 Revenue of $4.5M, Down 15.1% Y/Y

<p>Corrected-Biomerica: Reports Q4 2026 net loss of $1.1 million (adds dropped words “net loss”)</p>

Corrected-Biomerica: Reports Q4 2026 net loss of $1.1 million (adds dropped words “net loss”)

Biomerica reported a 17% increase in Q4 net sales compared to FY25, with a full-year net loss improving by 24% to $3.8mln. The company's InFoods IBS test has seen 100% of initial valid Medicare claims paid at the full CMS rate of $300. R&D expenses decreased 23% as key programs transition towards commercialization. Biomerica completed a $2.23mln financing and engaged B. Riley Securities to evaluate potential strategic opportunities, including partnerships and business combinations.

Biomerica Q4 Net Sales Up 17%, Full-Year Loss Narrows 24%

Biomerica reported FY26 year-end financial results, with Q4 net sales increasing 17% YoY and full-year net loss improving 24% to $3.8 million. InFoods IBS update showed 100% of initial valid claims processed to date paid at the full CMS rate of $300. R&D expenses decreased 23% as key programs transitioned toward commercialization. The company completed a $2.23 million financing and engaged B. Riley Securities to support the board's evaluation of potential strategic opportunities, including partnerships and business combinations.

BMRA News